~~CLAIMS~~ **Claims**

1. An isolated peptide comprising a sequence according to SEQ ID No. ~~86, wherein the peptide is capable of inducing~~ 88 or a variant thereof which is at least 80%, preferably 90 and more preferred 95% homolog to SEQ ID No. 88 or a variant thereof that induces T cells cross-reacting with said peptide, wherein said peptide ~~has an overall length of not more than 30 amino acids.~~ is not full-length polypeptide.

2. The isolated peptide according to claim 1 ~~having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or –II~~. , wherein said peptide or variant has an overall length of between 8 and 100, preferably between 8 and 30, and most preferred between 8 and 14 amino acids.

3. The isolated peptide according to any one of claims 1 or 2, ~~wherein the peptide consists of the amino acid sequence according to SEQ ID No. 86.~~ having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or – II.

4. The isolated peptide according to any one of claims 1 to 3, wherein the peptide ~~is modified and/or includes non-peptide bonds.~~ consists or consists essentially of an amino acid sequence according to any one of SEQ ID No. 88.

5. ~~A nucleic acid, encoding a peptide according to any one of claims 1 to 3.~~ The isolated peptide according to any of Claims 1 to 4, wherein the peptide is modified and/or included non-peptide bonds.

6. The ~~nucleic acid~~ isolated peptide according to any of ~~claim 5~~ Claims 1 to 5, ~~which is DNA, cDNA, PNA, RNA or combinations thereof.~~ wherein the peptide is a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

7. ~~An expression vector expressing a nucleic acid according to claim 5 or 6.~~ A nucleic acid, encoding a peptide according to any one of Claims 1 to 6, provided, that the

peptide is not the full human protein, wherein the nucleic acid is linked to a heterologous promoter sequence.

8. ~~The peptide according to any one of claims 1 to 3, the nucleic acid according to claim 5 or 6 or the expression vector~~ The nucleic acid according to claim 7 ~~for use in medicine.~~ which is DNA, cDNA, PNA, CNA, RNA or combinations thereof.

9. ~~A host cell comprising the~~ An expression vector which expresses a nucleic acid according to claim ~~5~~ 7 or ~~6~~ 8. ~~or the expression vector according to claim 7.~~

10. ~~The host cell~~ An isolated peptide according to ~~claim 9 that is an antigen presenting cell, for example a dentritic cell.~~ any one of Claims 1 to 6, nucleic acid according to Claim 7 or 8 an expression vector according to Claim 9 for use in medicine.

11. ~~A method for producing the peptide~~ A host cell comprising a nucleic acid according to ~~any one of claims 1 to 4, the method comprising culturing the host cell according to claim 10, and isolating the peptide from said host cell or its culture medium.~~ Claim 7 or 8 or an expression vector according to Claim 9.

12. ~~An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide~~ The host cell according to ~~any one of claims 1 to 3~~ Claim 11 that is an antigen presenting cell.

13. ~~The method~~ The host cell according to claim 12, wherein ~~said~~ the antigen ~~is loaded onto class I MHC molecules expressed on the surface of a suitable antigen presenting cell by contacting a sufficient amount of the antigen with said antigen presenting cell.~~ presenting cell is dentritic cell.

14. ~~The~~ A method of producing a peptide according to ~~claim 13, wherein the antigen presenting cell comprises an expression vector expressing said peptide according to~~

~~any one of claims 1 to 3.~~ any one of Claims 1 to 6, the method comprising culturing the host cell according to Claim 11 and isolating the peptide from the host cell or its culture medium.

15. An ~~isolated~~ in vitro method for producing activated cytotoxic T lymphocyte (CTL), ~~produced by~~ the method ~~according to any one of claims 12 to 14, which selectively recognise a cell which aberrantly expresses a polypeptide comprising the amino acid sequence given in any one of claims 1 to 3.~~ comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 6.

16. ~~Use of the peptide~~ The method according to ~~any one of claims 1 to 4~~ Claim 15, ~~a nucleic acid according to claim 5 or 6, the expression vector according to claim 7, the cell according to claim 10, or the activated cytotoxic T lymphocyte according to claim 15 in the manufacture of a medicament for the treatment of cancer cells.~~ wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

17. ~~The use~~ The menthod according to claim ~~16~~ 15, wherein ~~said medicament is a vaccine.~~ the antigen-presenting cell comprises an expression vector capable of expressing said peptide containing SEQ ID No. 88 or said variant amino acid sequence.

18. ~~The use according to claim 16, wherein said cancer cells are gastric cancer cells, or gastrointestinal, colorectal, pancreatic, lung or renal cells.~~ Activated cytotoxic T lymphocytes (CTL), produced by the method according to any one of Claims 15 to 17, which selectively recognize a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in any one of Claims 1 to 4.

19. Use of a peptide according to any one of claims 1 to 6, a nucleic acid according to claim 7 or 8, an expression vector according to claim 9, a cell according to claim 11 to 13, or an activated cytotoxic T lymphocyte according to claim 18 in the manufacture of a medicament for the treatment of cancer cells.

20. Use according to claim 19, wherein the medicament is a vaccine.

21. Use according to claim 19 or 20, wherein said cancer cells are gastric cancer cells, gastrointestinal, colorectal, pancreatic, lung or renal cells.

22. The cell according to claim 11 to 13, or an activated cytotoxic T lymphocyte according to claim 18 for use in therapy.